This dividend ETF's focus beyond yield continues to pay off for investors.
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
July 7 (Reuters) - Vertex Pharmaceuticals has agreed to buy Crinetics Pharmaceuticals for about $10 billion, expanding its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results